As previously described, concurrent genetic alterations have been identified in tumour samples of RET-rearranged NSCLC patients, mainly in TP-53 associated genes, cell-cycle associated genes and PI3K signalling pathway [6]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.